Peptide-based vectors have obtained interest for his or her specificity in binding to receptors overexpressed in breast cancer cells, probably beating worries related to reduced internalization. These approaches open up new avenues for treatment plans customized to battle specific breast cancer subtypes and glioblastoma by honing in on integrins